remdesivir

Details

Generic Name:
remdesivir
Project Status:
Pending
Therapeutic Area:
COVID-19 in non-hospitalized patients
Manufacturer:
Gilead Sciences Canada, Inc
Call for patient/clinician input open:
Brand Name:
Veklury
Project Line:
Reimbursement Review
Project Number:
SR0834-000
Call for patient/clinician input closed:
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
Non-hospitalized patients ≥12 years of age (weighing at least 40 kg) with positive results of direct severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death.
Submission Type:
Initial
Fee Schedule:
Pending
Indications:
Non-hospitalized patients ≥12 years of age (weighing at least 40 kg) with positive results of direct severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.